5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation

被引:123
作者
Zhu, WG
Hileman, T
Ke, Y
Wang, PC
Lu, SL
Duan, WR
Dai, ZY
Tong, TJ
Villalona-Calero, MA
Plass, C
Otterson, GA
机构
[1] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Canc Res Ctr, Beijing 100083, Peoples R China
[3] Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA
关键词
D O I
10.1074/jbc.M311703200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In addition to its demethylating function, 5-aza-2'-deoxycytidine (5-aza-CdR) also plays an important role in inducing cell cycle arrest, differentiation, and cell death. However, the mechanism by which 5-aza-CdR induces antineoplastic activity is not clear. In this study, we found that 5-aza-CdR at limited concentrations (0.01-5 muM) induces inhibition of cell proliferation as well as increased p53/p21(Waf1/Cip1) expression in A549 cells (wild-type p53) but not in H1299 (p53-null) and H719 cells ( p53 mutant). The p53-dependent p21(Waf1/Cip1) expression induced by 5-aza-CdR was not seen in A549 cells transfected with the wild-type human papilloma virus type-16 E6 gene that induces p53 degradation. Furthermore, deletion analysis and site-directed mutagenesis of the p21 promoter reveals that 5-aza-CdR induces p21(Waf1/Cip1) expression through two p53 binding sites in the p21 promoter. Finally, 5-aza-CdR-induced p21(Waf1)/ (Cip1) expression was dependent on DNA damage but not on DNA demethylation as demonstrated by comet assay and bisulfite sequencing, respectively. Our data provide useful clues for judging the therapeutic efficacy of 5-aza-CdR in the treatment of human cancer cells.
引用
收藏
页码:15161 / 15166
页数:6
相关论文
共 61 条
[1]   p53 Mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study [J].
Ahrendt, SA ;
Hu, YC ;
Buta, M ;
McDermott, MP ;
Benoit, N ;
Yang, SC ;
Wu, L ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) :961-970
[2]   The p21WAF1/CIP1 promoter is methylated in rat-1 cells:: Stable restoration of p53-dependent p21WAF1/CIP1 expression after transfection of a genomic clone containing the p21WAF1/CIP1 gene [J].
Allan, LA ;
Duhig, T ;
Read, M ;
Fried, M .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (04) :1291-1298
[3]   THE EFFECT OF VARIOUS ANTIOXIDANTS AND OTHER MODIFYING AGENTS ON OXYGEN-RADICAL-GENERATED DNA-DAMAGE IN HUMAN-LYMPHOCYTES IN THE COMET ASSAY [J].
ANDERSON, D ;
YU, TW ;
PHILLIPS, BJ ;
SCHMEZER, P .
MUTATION RESEARCH, 1994, 307 (01) :261-271
[4]  
Baylin SB, 1998, ADV CANCER RES, V72, P141
[5]   Inhibition of Transcription Results in Accumulation of Wt p53 Followed by Delayed Outburst of p53-Inducible Proteins: p53 as a Sensor of Transcriptional Integrity [J].
Blagosklonny, Mikhail V. ;
Demidenko, Zoya N. ;
Fojo, Tito .
CELL CYCLE, 2002, 1 (01) :67-74
[6]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[7]   5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy [J].
Christman, JK .
ONCOGENE, 2002, 21 (35) :5483-5495
[8]  
COVEY JM, 1986, CANCER RES, V46, P5511
[9]   Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment [J].
Daskalakis, M ;
Nguyen, TT ;
Nguyen, C ;
Guldberg, P ;
Köhler, G ;
Wijermans, P ;
Jones, PA ;
Lübbert, M .
BLOOD, 2002, 100 (08) :2957-2964
[10]   Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia [J].
DeSimone, J ;
Koshy, M ;
Dorn, L ;
Lavelle, D ;
Bressier, L ;
Molokie, R ;
Talischy, N .
BLOOD, 2002, 99 (11) :3905-3908